[
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "A patient comes in with a severe skin infection. The patient is currently being treated with broad-spectrum antibiotics, but culture results just came out:\nAmoxicillin - R\nAmpicillin/Sulbactam - R\nCefalexin - R\nCefazolin - R\nCefuroxime - R\nCiprofloxacin - R\nClindamycin - S\nErythromycin - R\nGentamicin - R\nLevofloxacin - R\nTetracycline - I\nVancomycin - S\nTrimethoprim/Sulfamethoxazole - S\nMoxifloxacin - R\nLinezolid - S\n\nThe medical team wants to narrow her narrow her antibiotic regimen by the time she's due for her next dose (in 6 hours). Which antibiotics are reasonable treatment options for this patient?\n\nAnswer Choices:\nA. Amoxicillin, Ciprofloxacin, Cefazolin\nB. Clindamycin, Amoxicillin, Tetracycline\nC. Vancomycin, Linezolid, Clindamycin\nD. Vancomycin, Linezolid, Tetracycline\nE. Erythromycin, Trimethoprim/Sulfamethoxazole, Linezolid\nF. Gentamicin, Levofloxacin, Tetracycline\nG. Tetracycline, Vancomycin, Moxifloxacin, Trimethoprim/Sulfamethoxazole"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E",
                  "F",
                  "G"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762204458-Q1YDpiQ3T95M7iXkzTrm",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"Choice C. Vancomycin, Linezolid, and Clindamycin are all reported as susceptible and are reasonable options. The other choices include agents that are resistant (or only intermediate) per the culture.\",\"answer_letter\":\"C\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": "**Evaluating antibiotic options**\n\nI\u2019m analyzing the antibiotic choices available. Gentamicin and Levofloxacin are not acceptable due to their resistance. Similarly, Moxifloxacin and Tetracycline present challenges. The best option seems to be answer C, which includes susceptible antibiotics like Clindamycin and Vancomycin. I can mention Trimethoprim/Sulfa (TMP-SMX) as a susceptible option, even if it\u2019s not in the selected choice. I\u2019ll provide a brief explanation and format my response as JSON with \"answer\" and \"answer_letter\" specified.",
            "reasoning_details": [
              {
                "type": "reasoning.summary",
                "summary": "**Evaluating antibiotic options**\n\nI\u2019m analyzing the antibiotic choices available. Gentamicin and Levofloxacin are not acceptable due to their resistance. Similarly, Moxifloxacin and Tetracycline present challenges. The best option seems to be answer C, which includes susceptible antibiotics like Clindamycin and Vancomycin. I can mention Trimethoprim/Sulfa (TMP-SMX) as a susceptible option, even if it\u2019s not in the selected choice. I\u2019ll provide a brief explanation and format my response as JSON with \"answer\" and \"answer_letter\" specified.",
                "format": "openai-responses-v1",
                "index": 0
              },
              {
                "type": "reasoning.encrypted",
                "data": "gAAAAABpCRs0YdtVu2Dj85CBI1P3KMxGX_dlZAqr369wP3uJOV-04nlgqBKhuN3uE4lpo5UjF1xZV96OoTmWtoPsLSrDycIXCduouc4DI5P6wf6t__ekPCm1yw6pBLHeSTQBOE5jFi751FL4gjO4iNbjovKbVfbZms7ws-O9jQT9UaNIfmEtvGJyIIRn5gFYYgJHlOZu_T1nU95tPcnp7ZD5KWG6MQlkvprdreuqf6d_C9bCi_A5erQtzCyJoCwodCTO6_A88_zBUL1GQIU6BOJ0TT7J9DZNCbkxuiDxAwl52oS02lKvuaqviCuQl_rauSaDFtV2EcYIfJ7dwsoxbiJfiCoWECBhXsHyeCR_wDJ7FhNTvOaiF-wLUDu62tfyvay55RLPp7tNgvhQ4G8O3qUulrCiAKhkZMZsI4P8f0kGqPNOIou5OKVIH35KuVLME02HjJzNS0hXAyMq6bU2G2UGxhr-WnZwPxp6p48xYwej0TnVu1Ue_MH9rUaw7SB7ro4TTRg1E9FaYK85kaJiTMeounpQTZzsTg6QcdbEshrMnGDItUcg8RnPTO3EX7_tTM05IrJkm7MdMLZNmDuHbCOpCfm9zYTMEjMzg1uFiZwzNMJUYmLOoinCgPYTcoKkkAjgKgxlDkBPpb6TT3CvXtfonRevMS__5-KI3imIAGRGh8BxC2TmP5hWGVHnXLX0NgX6AeYBwQVBSuSqjj46f5j1rNv5IfEGk0Nn992Q_CqNfnAXlKNhILbbcuPNujqv24625D0xWaWuPskvkbfIFUhlVR8_iyTFV3vkfqhguvCr_hs_9CyDXHyrB_3rCgb8EuG5_BxnA4gRO9x4haCy-a0I5-nyKGLEhHrDmL4_JsJwZ10GjC2b4LytvxQZG-hyvNlThhzyvL4LskZynXFppmABE7cVJZ5ZDmxsPph9n7iApla3bXwlvyPAlPW5O-DAgwayE9_ZW5cVTpl6Iln_4A0Y8Tq4PbXwUBz8X3mZ-pL0MYgeeqAMhlutBaMB_uGGHOp-Pl6hF0ObKpv9dOLI9U8onongYdCYSme2NZtZQl2mPBor1Uv2gM-19e7Q7nWlYdMp7lm9ULr3s2gE--RLKraw2UoNIwDOS9GbPX7NNUGR1PMP6Tt9xWKDkpOEUKfd_EyFzQo6NoAybrDDGqJz0kw6o_J5AeMxqQrECMxWAYsY0hHP_DO5ej0V8rrS2cV8co_ua5XgcXeJ4GZKUp0M0Ds1OQwvqSbPtqY2E1gcnEfQooK4FFy5IerWguu7BrsFFEg7BMesESL4PLx4bc6OUyiAFewBGgez1AjDMCcFsy2K9IWGRB49LeeTNNGWoDPUQcNE5tczVFfUwAWZzDxm6aSJp9tLhBShzB-n7CuLancW5-wO3sypOGLtQtRgwD8bPfPTKByvNaUq45mwiCEXVFi_Bx_WO2cyd9e_B6cGOZo4rTO86OmuNLY65SKzvVjfJZpSjpbLs-iNhXSYZGk5ux-U9_yn9ZovKlARhKyMppCIIOwDKejyDdSt1qSGi2v8v508NWAYA0H35PqlLaYA7hchvJq3BvflMbw4QZc1XkuSjD80WGTNKTDLBY4hiAltx2wjh9j95iSqk8bYqbSwHIF2Vs1bkLMSnt3O2bwaBsgd_UnG4XJmLGYzdvUmzkxMOmt9uokuDrSZu9tYyIFgaBjcS_-T4NvwVv92ecudzYetBr77LhLGl_SFjZPYBvhMi2HxXNUMVbOxMzfBYOUYmxGaMvBYZSjdE2xk1V6_4yPYfTICXWXRByzDeIItppoLxBcsz1IMRe6Mdw2o1QgtuIRx3xGoTWFoCv3Sfj3VJuT5OXNdJy504UPzmYBJuPaZ75DzXoDvOofzM_RkZFROcBuE1IbW5TdFSek_H73igHJjgA-EoJH7F5jIW_XcP1elI442lhf1gW0TZCNfNdHgdMpi29Y5nm3BIBQinqnUqQWEaQwkYiokPbqp-UvKHRbfSDQERufG51TTdWKvoE9IIr97tX25b_FimvnXEFM5ApmVAETw4nyrZb4RgnoBuHFbm851UkIutW10_xsehe2J4rG4Ki2tbmt4uuAO-qVwyhUPOvlhm4FYZ6R_eH4v-eW9F-TqRovul9c6TYk4XN9kQNJMJC2hi7hINjxjzPgfdOBot3BCIJJMnpdWiGtsLPr3XkkI6oV0zRjcSj_QTfbHG8662oosgtay3pvjvI53TbUQEyXxlT3-sFKI4Q92jHhJXwZ4uTI7QHIUiB86vDigrIUIJ-vW2aEb7S7U5h5FhTLkmaYJ-XYknqc-PtqArs8F8S-oNrTuxNxckawM35iF_Ym3cF8Wo66NEdA6oP9Zsc3LhiK49qMIIBK8lFgCPtVky2mOCeLo-czypd1rA-Q0tj9TFZjPI1aeogLVeVrWiqFTtjPzhUo5m2h1sFdyOO37Q4v0xUDnDk2ARM_Tbcxmvr_O70DJNjWDlVPc3c_iZ68oQQbqRvuUJhWoSWRCKu1zwvmH85NBcnxed23s3NjCr0OVdh_bdtu6IL0v05v-asswREQHZ7ii03nj49XmDzbgt3P85qAPK_4M_6gDyOVK1yJ_WGJ9_Hb1yNq_p8kIOBq12VmdCrAuyR3BtpHysMfcnmn4gbbjEVbA7S-TOX2q9W1E8GKE4SJGw4JNw3c6c08miI0OpXjT0e0Hi8726yKZbU0_fDUWxBdL8E5ABd6JO7-yOuCzFT7M5nuFdrsSACV2_w7Po7UDV3ZuYg4mnIylg1Pi1Y2dQi3yV4gAIFt08Vy5nrqOsKb0Q35GjEBmUWfiG8U1T3E_MbDmjRowF8IYRoj689DAKy1ItuMQnKy5--pNLysV1P6TtRKZHXPHA9PbXr37X86hiuhvANpcJH4LSjE6_RWVd3p8vR_bRyug0W9jZbjH6Zk82-urFv_663hWLosotaHTB3ExWjr56A4WZU7OFXqt60RDmGmiiVbfapjE08B184_iKj_in5dl6cL30qObgDRBImGucDvrMOvZ-z8XB_RLHuDZALZiifExfF67nXo2gaOy0X9CbaCmp0eqX5K6OTqDbQXIt3QmgI9UwQfkvhD0HhKkM1-Dpc0Iy5ezhjKjPEYV8KnZSbPsL0d0WxU39sUCHaOLAksbhP9ign0yeicCGtGiIhDTw9Ujf6xXma4AvO0EqU8yqXyxf37yptrlzUs34RjYN0OXeC5fRKZVGchz1dbj9rMe-d_pCCPNmnVSXS8btQ==",
                "id": "rs_0aa6fd9ee485e4500169091b2b66dc81978d14465ec62085a4",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762204458,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 509,
        "prompt_tokens": 358,
        "total_tokens": 867,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 448,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.0011075,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 8.95e-05,
          "upstream_inference_completions_cost": 0.001018
        }
      },
      "provider": "OpenAI"
    }
  },
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "A patient comes in with a severe skin infection. The patient is currently being treated with broad-spectrum antibiotics, but culture results just came out:\nAmoxicillin - R\nAmpicillin/Sulbactam - R\nCefalexin - R\nCefazolin - R\nCefuroxime - R\nCiprofloxacin - R\nClindamycin - S\nErythromycin - R\nGentamicin - R\nLevofloxacin - R\nTetracycline - I\nVancomycin - S\nTrimethoprim/Sulfamethoxazole - S\nMoxifloxacin - R\nLinezolid - S\n\nThe medical team wants to narrow her narrow her antibiotic regimen by the time she's due for her next dose (in 6 hours). Which antibiotics are reasonable treatment options for this patient?\n\nAnswer Choices:\nA. Amoxicillin, Ciprofloxacin, Cefazolin\nB. Clindamycin, Amoxicillin, Tetracycline\nC. Vancomycin, Linezolid, Clindamycin\nD. Vancomycin, Linezolid, Tetracycline\nE. Erythromycin, Trimethoprim/Sulfamethoxazole, Linezolid\nF. Gentamicin, Levofloxacin, Tetracycline\nG. Tetracycline, Vancomycin, Moxifloxacin, Trimethoprim/Sulfamethoxazole"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E",
                  "F",
                  "G"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762204458-zejnNljMRBtPjlbw3sUK",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"C. Vancomycin, Linezolid, Clindamycin\\n\\nRationale: The isolate is susceptible (S) to clindamycin, vancomycin, linezolid and trimethoprim/sulfamethoxazole; many other agents are resistant. Option C lists only agents to which the organism is susceptible. (Tetracycline is intermediate and most other options include resistant drugs.) Note you would choose one effective agent rather than routinely combining vancomycin and linezolid together.\",\"answer_letter\":\"C\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": "**Evaluating antibiotic choices**\n\nI need to select reasonable antibiotic options based on susceptibility results. The culture indicates that Clindamycin, Vancomycin, and Linezolid are susceptible, while Tetracycline is intermediate. I should focus on choosing therapies that are either susceptible or possibly intermediate. Let\u2019s evaluate the options:\n\nA includes only resistant drugs, so it\u2019s out. B also has resistant. C has all susceptible, so that\u2019s good. D includes an intermediate, which might not be ideal. E has resistant. F is also out. Let\u2019s stick with C for the best choice!**Finalizing antibiotic selection**\n\nI'm analyzing the options again. Tetracycline is intermediate, while Vancomycin is susceptible, and Moxifloxacin is resistant. Since the goal is to use only ideal agents, I see C as the correct choice. The culture susceptibility shows that Vancomycin, Linezolid, and Clindamycin are all susceptible, and TMP-SMX is a suitable alternative, though it isn't included in C. I should emphasize choosing agents with susceptibility. Next, I\u2019ll present my answer as a JSON object, mentioning the timeframe for the next dose too.**Considering antibiotic options**\n\nI need to think about which antibiotics are reasonable treatment options. While Vancomycin and Linezolid both cover MRSA, using them together can be redundant and potentially harmful. The question asks for reasonable choices, and option C lists three appropriate antibiotics. It\u2019s essential to note that while these options are all susceptible, you wouldn\u2019t want to prescribe both Vancomycin and Linezolid at the same time. The instruction to narrow the regimen for the next dose in 6 hours is key here.**Selecting susceptible antibiotics**\n\nI\u2019ve determined that the best answer is C, as it includes only susceptible antibiotics. The other options involve resistance. While Tetracycline is intermediate and can be used with dose adjustments, it isn\u2019t ideal in this case. I should also mention that TMP-SMX is susceptible but isn't listed among the answer choices. Keeping my explanation concise will help clarify why C is the right selection.",
            "reasoning_details": [
              {
                "type": "reasoning.summary",
                "summary": "**Evaluating antibiotic choices**\n\nI need to select reasonable antibiotic options based on susceptibility results. The culture indicates that Clindamycin, Vancomycin, and Linezolid are susceptible, while Tetracycline is intermediate. I should focus on choosing therapies that are either susceptible or possibly intermediate. Let\u2019s evaluate the options:\n\nA includes only resistant drugs, so it\u2019s out. B also has resistant. C has all susceptible, so that\u2019s good. D includes an intermediate, which might not be ideal. E has resistant. F is also out. Let\u2019s stick with C for the best choice!**Finalizing antibiotic selection**\n\nI'm analyzing the options again. Tetracycline is intermediate, while Vancomycin is susceptible, and Moxifloxacin is resistant. Since the goal is to use only ideal agents, I see C as the correct choice. The culture susceptibility shows that Vancomycin, Linezolid, and Clindamycin are all susceptible, and TMP-SMX is a suitable alternative, though it isn't included in C. I should emphasize choosing agents with susceptibility. Next, I\u2019ll present my answer as a JSON object, mentioning the timeframe for the next dose too.**Considering antibiotic options**\n\nI need to think about which antibiotics are reasonable treatment options. While Vancomycin and Linezolid both cover MRSA, using them together can be redundant and potentially harmful. The question asks for reasonable choices, and option C lists three appropriate antibiotics. It\u2019s essential to note that while these options are all susceptible, you wouldn\u2019t want to prescribe both Vancomycin and Linezolid at the same time. The instruction to narrow the regimen for the next dose in 6 hours is key here.**Selecting susceptible antibiotics**\n\nI\u2019ve determined that the best answer is C, as it includes only susceptible antibiotics. The other options involve resistance. While Tetracycline is intermediate and can be used with dose adjustments, it isn\u2019t ideal in this case. I should also mention that TMP-SMX is susceptible but isn't listed among the answer choices. Keeping my explanation concise will help clarify why C is the right selection.",
                "format": "openai-responses-v1",
                "index": 0
              },
              {
                "type": "reasoning.encrypted",
                "data": "gAAAAABpCRs6F1RxOMYYrDfGI_Ol-Hid9Rkwj_e6I7iYqbIqpQjh-dZ7rTignDrRKSLe0L1reEvaip_upS2HYG7rzO4h8rH9yM2zj-mi3A8ZHrjeqbG7uGXZPKqhUQfl6Hxj-4eWd_pWM7Pp3smvedCzXRQUXBGrEQWfl8qWvQ3QpKckK17X7uPj-bPw_hJBIQ-kjCgDAIMqUqGieK64Lh8sQJuMxRM784X8vfSW26tukM04boaua27NYyyu7S-m4875-PNY3v5FU0LgoQlIf-_zIaGgPrmyrkSn5zX0jJ-la9tnpDhf5B_I6fD8RFF6onJ7FwKZS6vAeM10_J8rbZBltR5s7NhbB5-PvFSFsnU5Ln16zUNC9kMGqAYy3wxaTJQly-rov2QKyb0wX0uKoJaazvl5h4kG8CNYwo70sUDTBRSKhPTNtnPmOw4Kqo2gR6MI5eUO46h9Wumu7ddYkMxt7qBkCd8t75pb991zNHbiMDi-8F7MwbS5Gw1vgV26SoatygblyIKmDrMwwVK85RbcKWjF_8ys9MoyAH82BxbVgi38HUZCqts06spTPUbskqwMMf5DDnbiGVOn0Q6u54yFc7wrbYad4D5P_IiClzqh6ntWodPrwx27uFsBwR1NRB0djQXLfiXhmJDWWFlmxIMaPj9A0QC-2Jq6F8H5ntN0ELQceqt8WWcQbNOnV6jSiNQMU6akb1iM_v4ix5r_erP4ztMfufm5bhFiM8iHCAKFD8LGPEmDfGoZZMZMFgjc7uDyCsk84RT9wStgBlA2syQgJibLfA9Osz4e6-yM2OHyIyeoyqOb4LurtQxgmRsOBC1FIo4F8RuF59GVQEHOGNj8MvoE8hKcTdqwUK9dNeX8lClDaNbWGliWxg4XPYHB9D2tc4mX7hN-r2wuFU7Ds5xGPR9aV958XRlnA530T2CC3O-PlvMTK_RkKQTxJ0qjnqyfaOMVM8WAtT2g3p1MRst_WghTEwYk6b6CThpf1cWDcQQFVdc1RS9xt7_mAJbQC4lFbIHn001zpQyPnZqQSBV6bHPCIgkpffzHKdH4SAuIvKPfZDf2ft6SAbAbs1A1uxOc4jVMq5N1Aok4hBu4btmqZPHmT70GVKtbzHqustR-LxBM53bSgaZ8rt2dmKJfQwFYtH29sbL2a0XzbSlk2aPDUVpnRGFJnqT2Yp5c1yVQutHdI4E591yaH55aQfwftykZ8sP_EJtpaKgAAlz94wQJJzNft-WXY5gI-BnVyV9J6HYVeSY76jbWZWej1iIwP1xkTDYvEh2VVs2whgrNqvUXvM7AMwgOPszWmwY4liv2vUP8en7bmH9dBBrqSRaUkqToEUtQWW5jxXBnayHNzpy9OWEoydr3Wb4ueryga0XSuQVPdSFsWk-PjJD_BsAKTe3l41WA2F5j9H3Hlt0myVbB-PCrjurI7z4MvoUMGEmSKDK3-WK0sO8H3yqDnz1pgpuDoTbaDehV1K2JoJu8plhiNoFRDXyEDX5cLIHawH4iho6a9fXEs0DgAizTvd2QG78n2OwKzvmaJDVf3bUcLsHSaOAcqhxk6aclt0GahhRKqHmacR4EWQdwEvUnwJbs9Kzrt-rGQrsGXExp6tEAbpOO7n5FoPg1XxZQXbxmB2QlakPtpZIwLHbGCWqPn5UZ_yesy0g729_2xOY14K5i5Xo-ciJIKJN6Y9SALGQFDTpEDWNQ5EDZBsk0dQY6UdD_ZdSpk3Lc-56ARdM28_s1_HwuMOKPvUBuyiNcyXVz5UOP5dVJiga9EFd2RPLt2BQA2-aIi_lze2f-tOArMILsDPlC9D4PhzFuhCMC-nPKyid4QVFbzyOLTrqVAv-Q86hVGGFyYHG4vobq8EtpUmiRzzGXcVEECEMnmSPR1nlpIdIs9T-4bH9IWkW0fEtxKdjzd1CIpbH6oE9tpkpsU6IH4W55gHzzEjzHFZzZnQ5EcCM2zcu67JuKXIPVNGeCgCptdx9tRi1O3jSglyUCBGjGBO34WwTVe1GRIbKEU5iMmJpu_tAwOy3O017OzFw2YOy0kzijDiMXP94mqDFF8mfmmRr0tg0ezLZlwcoPSqJCjmiU3k1szwsGBKKVx6TnECkJx8B3PXs2XvpI22C14zrwF7m32uZFhwV4Gli7OBLpAY9n-ASl26upYHAGV6aXThwXlqIgszv7oQojlg7fc6Jpnz7dSr2yxV1iHYpelao5Zkv1J5LPVfLyKqxcKxyZ8UPddQhIMqJc7b9iRRlJAhYHbsprJL-X7-Yw5ONGH1fXAGEbgpPonUdYnL01JRLnq8dnyiGzagF9FHFhnaND4WIg3yx5rx_N5C2Ij4EhYrhJe5bZSwGCp3Dcdby4CcEHAHl7rkwSfkUUSU2p8Mac3a_Z0Jo2Mb6XGBCe_egE0GJa1op2Z6uTvkgqL6erUWT8vQ6kVFwBq1aTXo39cipudzdfSYI-4U5HZBR2vwWCnxungF7vDylkOKtuihItLtdTBWWIgt4uxvXXkfS3TVASssyuaqOY1LeBmIz7oOIUI87wqfLINSdWLkZ1Jhzs2U-mToMpn5yJolKMSTj86YF2OBvD7n_Vs9zUF38JckEahD-GfeahZh9R0kkF6P2y-TXFgC_Izut1JqRXu5wzfxGQ_GMzJZFpIZNvmxwnlLUdmgJiiJSGTWouQ7aCYxrqSFJMjIyRn6A8vrAJzzbinpHxp4XIixTHmqFvC0xmXPw1qDdOWuFJH74mjH5QeKWzvFQ--BSmLWMY7ZfrlJyaTsRrf3gsWpMFESMFngzPaeRc2TeZnfGg34M7cc4GMn77B7bQMxy9eH416Q1gBSFTWP5rrrqiiJPQRyb0_rNOmTiSrUNlRsBuCAau-oCNnSC0f_WObpQwKiR6NWVhIuHZ2Gnjekv958cLhiRXWDt3L2HaGF-m0MBi4zxG5ozVBHHDxnqRWDxztk0TttaiAwymZycS9btL8X6uPLv9biYgUA_C4vntUkAXqzb-MmQ5SCxUweVoI5CmUYehGpCflVRCrJ23c6I3DP7syoEzJGOsnZtCG3dlJMdYxxbiO6AFkqdhOo7q2TJya2qN-4tK4JY-zdLGPWrou86fpwFSc3NFzFabz7r7TjkXy49wlbNVYY7G6gdvsTlk297SsSe2d0lipInXzw5I6UgFMbZtVV9sVKJ6Ag-CnUtKvoXgITWCdPi97fi-QnXAg5w5uH7icVLH9wTWa8domIQvA3d_CDsnl0Qu_Dlju0Op1Vw5M5dpABmNJX9nCfxDVR2UBG47A75mUWvLDGLjTMzzL_7nC46o0QSgnSefzGCQ94PXUTcUF7Kegp9HyVrYB4JIUlYVQAoh8xR0KQt2DDOAomNhJAKx8RT-c3IO7JNmDtU3p4uKbPYqSIQ-HSKzxSXMBXKhohkNCnYo0v2LrkBOHr_6crnRGHlI3zgO0SPE0fE97CScXkDQ7o0dFtu3FgeFtQ9LI_EVYjxv7_YRixCglHs2hn8i_z-6vXzISS3hxh6yTgfabdKe4ZtK8P-sSJgy8tI8PpM-medJ1fLxQ61gybZF2W0FGVpClEqrM8RXaxQkiiMa0jW8X8MKcD-RqPLpm1fQxKqAuZtFqxNHcMueMDgeqrCps7Si65xqZH5CTcY-ugR_0j5hWaRt-Zkkq4-0zqDuR84E9NpWGgMq90nPo1cATBkTSNUEyQAyY4bjGFHSyQJ-OxFG--8Gx3hHNJMS1GsjDOmHv7OfL2bSHMeO8cnoQSCZPflXnMJ2aJHFLqSMGALWN2io_AhC0iJB06OS_fN0X5HFdNzljMtEO9VzL66TmA8HoaJ7XQQQNixwKZXzPz-iD0_k-6-O77D3tVfHW3o4msjdnQFNEyuak2I4jff_mj6xzPvGBEwpk2SaB3a-oFIM_Ia7ZxJzp9GiucR__DsjjJQdmI1XqjreIGFzHFdJCs-AzErBuUS0ChPCaAawLKI9GbwRJvJQL_beqqaERcDdm1ZwNn7mHnt0ev_lGf5OGnTLtGcx7AJLEOmRDo1znxH_T-5TaoElHhjB-PDUhlcXMGO7RS-rDsh8zU43bz1FolyGC5k5iPqJbRdMzO6j8twimGWZUJoYp7I_x_Rv36gRBBj5IHDYOCNbP8k10EGocPOBjKD6WN6JcpxKGcz8Lw7JAyyvj-tun95fWEpsQcdHcprl-Wc4sEfn9ECqnDP_jTXo8F5UNiyD6ZlcGUsWPzSnIvxq2b_MvATU1tbD0zw3ocUP5SHiY-EYC11ERAhlvYcfN1FQuP-L6rxJ4rBJqLqIDXhtAbabBGlbS613rhdUuQMzbE8tpZpM0Hcr4CZ-G3pQcZJsSWY0G38gAUNKmXZur5PUiBsfIX33Mx5YuyxHNwUGCjmSKE_lXCT0lfUqZDOsURy49RitAgTLV9a9Fm9ITV8iFtfyuAoLKlPL0AIuN2m_Klg1u1wraW0B6Gq1DihGNL-6JbUk2VGq0U-yzc4CRoTujKcU9krd4aOJYlqdU7fYEzSKdi0oL818Esmg4lG2qd66anwjaZSvVYJYN1MmF7FpzZJmnj6dqSc3Lb9MWU8QqRZbmv_oyZHqAZPsvwCJGm-k8DSN-o-C9LReph0ZZogWgCJ9bCp7BG2t_KS1w85goo-8-lLfKvodcIdDyTgmSyu9JLb5y90dRjvYXTLSWRdNSySJ9be5OV_nd228RZPqkupcuy0DVsSAHuP5tiZw036jtVIeTq37rFOYnQ6IWLM6Wf8jk5ze3Dz8ra90JUYerL4NToLcMrbFLeJzBXaBF6lcfRKmrddMoHiDoaq-KFYKx1Hrx1KxgHTiERPB6cOc_BH-9w-inFM098PSICs0roE3TTOb3jO6t8CNoGyRa5XEWKIf1UJtp6xu5cqFZyrYdo_9FfXI6CejiJjUSHlRsTZBW5nuriRzPSKGpzboTDfwyYiXIOKdncNZUXZuVGlTfj73n7fMn3C2hleSobiWdb1q6eMA5Zqqbv7sq6x5n-OslANaX8JIW8PlLXoNglGze9Hx_35AH8NRtggxP9Mdv1j1AIcesGj8ROV1v5SIJKfm3fkjbCezFmzrKUxmXYTRvAhGsUWTwLZHBX2HMmTNuR9ibxgMyhEk-bPphPrh4YJ8mM8BI8c62e5e76k6s82-yJexAiucrFakQQ-RDHaHbdUzaBGpylZinoXSGOC63FZvayKUq_5ZoRyzkrLEKsJheP-SiL8GLhh1TLbsjzfGi0G4M4ftM9g4OPALZklwwEqa8xFNZ6PqJKZYf04nPw9_",
                "id": "rs_0144c1867f864f210169091b2b82388196be8b27bede6fed7b",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762204459,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 892,
        "prompt_tokens": 358,
        "total_tokens": 1250,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 768,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.0018735,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 8.95e-05,
          "upstream_inference_completions_cost": 0.001784
        }
      },
      "provider": "OpenAI"
    }
  },
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "A patient comes in with a severe skin infection. The patient is currently being treated with broad-spectrum antibiotics, but culture results just came out:\nAmoxicillin - R\nAmpicillin/Sulbactam - R\nCefalexin - R\nCefazolin - R\nCefuroxime - R\nCiprofloxacin - R\nClindamycin - S\nErythromycin - R\nGentamicin - R\nLevofloxacin - R\nTetracycline - I\nVancomycin - S\nTrimethoprim/Sulfamethoxazole - S\nMoxifloxacin - R\nLinezolid - S\n\nThe medical team wants to narrow her narrow her antibiotic regimen by the time she's due for her next dose (in 6 hours). Which antibiotics are reasonable treatment options for this patient?\n\nAnswer Choices:\nA. Amoxicillin, Ciprofloxacin, Cefazolin\nB. Clindamycin, Amoxicillin, Tetracycline\nC. Vancomycin, Linezolid, Clindamycin\nD. Vancomycin, Linezolid, Tetracycline\nE. Erythromycin, Trimethoprim/Sulfamethoxazole, Linezolid\nF. Gentamicin, Levofloxacin, Tetracycline\nG. Tetracycline, Vancomycin, Moxifloxacin, Trimethoprim/Sulfamethoxazole"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E",
                  "F",
                  "G"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762204459-sOXmkWyVJZYrWuykxpqq",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"Choose antibiotics the organism is susceptible to. From the susceptibilities given the only answer that lists all susceptible agents is Vancomycin (S), Linezolid (S), and Clindamycin (S). (Other listed options include resistant or only intermediate agents.)\",\"answer_letter\":\"C\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": "**Choosing options for TMP-SMX**\n\nI see that I could mention that TMP-SMX is also an option but isn\u2019t included in the other selections except for E/G. Since I want to pick C, I\u2019ll respond in a concise JSON answer format that includes an explanation and clearly states my answer as \"C.\" It\u2019s important to keep things straightforward, so I\u2019ll aim for clarity in my response!",
            "reasoning_details": [
              {
                "type": "reasoning.summary",
                "summary": "**Choosing options for TMP-SMX**\n\nI see that I could mention that TMP-SMX is also an option but isn\u2019t included in the other selections except for E/G. Since I want to pick C, I\u2019ll respond in a concise JSON answer format that includes an explanation and clearly states my answer as \"C.\" It\u2019s important to keep things straightforward, so I\u2019ll aim for clarity in my response!",
                "format": "openai-responses-v1",
                "index": 0
              },
              {
                "type": "reasoning.encrypted",
                "data": "gAAAAABpCRs0abkqD93d33AjpcIJpIAYvb2U-ipOxqxEfz7Pp8hBnBc3kyGDbiJ1BFB5XFmM87FPJIOxP6j1vnleyRN7zPdA-kdqoB8Q5KcgnoNF2cf8nKgvbGUmpylhTdXQBD7ypqEapIEbT6Y5AjtLZ_vrNev04Sw-ZSLD-uMiufL_2uZ01cEvaPrMUOEoztY20vhQGxMdCfY7aYL53q-MncUtKt-CbvAuBX_l_EPiBXI1cU7ewWA32FM1kb4tFr7-GXKKz-3OxfatjhAtabPxDTyMWRunP9ub6Tp-9-SJsjWLet5PgzRJIdwyVH4LHzx1VLodgl_AICVVhsBZWwV7MyP6oBtHmTiao0lMuo_al9A76eBkj6msDS3atVQrOqOjRWgQKuG74_UIPFloDTW66VnjxoVXeCbdaHvALPSR5t6e-mzzcX-koXws_QcToCzc5MEVhkXte1qkZk0OpI5TzCTKccIa4UyzpSvjnsyPc8C6kN3E60eNAUuwzh1Ow0HSG6Cdt2XWEA2UmmUy08aLSI93KMiDeZUS9tzNCdcZ0NwACdCjOM7zx6wLsipkZyNgTqVyZE5KexyVr_RR0SA9VpP7SPKLj2IgjeXq1a46srAjrhhjmqRviautfnzVsPYYhnaXP_4w-pYI14h9P6MGG8hcZYB62ZX-Y3A3j0wmy2OfiEfr75KFLKbObvmaqZebOex0VwbcYICYSXIyf3R0BGoiuJ3STSvaiVu0ETIZ0cdTUa3NtGeEXtlnc7NlsAh1OZyf2Mj12t9YfWwLQuqn4HmtUKIXO2pk5cF1r7ZyxcsOziuDmuGmL0tatLEcpVuTj8m_0agVNhfMNrloNBstmSJHrhJEuOHJEYdEG62lc0oIoT8B3M0yT_-VMiey7B8171MasvSGphT8WJhu9ZFFgVMGY2lMr_iRXyK_LEHe-okf7ug6Rx-dGHmoWCDRqMcd2S-wuPfzIRvKNWfNzuCJkb44INhgScVYV2EAUi9Jx_KwnWoONkZEiV8Vqap0AHabiWA9XqhBQ7T7TlVp_edthnsxCkx-r4a6oBdcz0DW319wIPV0Ma0Mh9h6T8cqwhz6uRNjurAZTSR1-WkQBef87m8QMdSHuXvl33uj5ZCx6c2gvjAMF0wR6ZGeps27EEbPAKwmC_Pn_lnyIqLKbJ6vNJj0XPGA_-eJGO0uZyWDBAD5E8f2MbsVP-w-Mtnv9QDIFVr6Pz5bj2Ojx8S_gF5DRlEuSib1JiSTWHexZxVeRwRmZ1Zuxc9DhYXyLHjvaeZHa-5rZD-ISkAYQTKHeccjlDU3wuMl7Z131hRpY7MjSGbI5WMcb4wlvGHzaRr06_UpKD1_pSf-rroZl0YDLwoVAptz1PhM7cq5ilOfOMOhvnXwcCqRClSMr4Sht1k9C0TdOAn8iHg3Oy-etbG50A6Z0CDrYlV0XOlPEKcPuYBeK7fIvERh5YoeNBLwMaCkBgiNI_UA-LnaeWGOi8heYs4isbNdqLbP7_l32wnS6p7lm98pmsJPh9BtpR1v9j0ZTUiP6_ABuI96swtgLD2wyXPPlS0jr0eykt2JPEd4MYO0Yj6n6vf2YjIZASVJN1NAyEd-CRFLrjxzF1p7eoce2l5wlswgr9nAliAWzCCy3G3ToPGcL9FEXnj2bcRUedUp8K9v0bMDrJiEjpwIhIHMIHbK0OXe705q-mikTxsogKmNJqjvv6L2cB-6oRpG-9WKuGSBqHvehTs-OZgwwH6-3CldVTqkfGQYhwllZQ8BCMTO2IZFdeHG9-v_usyTwa80nSc8xAX2wlB2ZZ_4KcBmrn9_UXqAJZlsTt-SjW9nPUOjdVJmyYfT_KjKzlkWDP31MQ-WPZ52iKqgXSNfHwat-Ie1saM7L7IMUgJ0xwSplW52DFp_zD6MXgi5c62-iQ8M54vlM8ejMIhQsu3N4PmUfvTohekGVbM8Q8fLjdUr4pBm_dR44H0DuAw5JRU8h9iS6fVgtz4VzKvp3KjlDYQhupGCCqjz1vWIv0olhuYDP9Y_Bq2_do-dcjNnRmBwnNRqdIhooC4aLowRAx9RcLwr_DFOon-jN6Oybc8FnPxsYrVYj4e46Vy4LAUz8JcJ4-PuybUD_WKSDtnY5GuLLAcQCT64vRfe8sulOKZY5EoeWfXVlOI0TwGWffFjdlJJof10t0Q3rmSHjgH-FlyQpJweM9v15-jdayl3DhSCRvzPMHIJwQ8hAqb5wAzQfts6lxvzLGRW6r1nd_Lv1uit0gQpO59gj4i2AMxLF8hvxo-yMiZc6CBz5pPS6HN6Kzb1uMxV5qmy65IvOC95SHtGmHJRoSwIjIFgAf-uluSdUazrQSZKpWM3hB4Iytlf3NPVe4-ZgVfTu1_JZLGZEbu9Dc9N_Cem4IqA04TVXN18TSQ_6zKjfycSsarHOomtVYSUTQDQPr0USvCydVen-c9kePqFDE-WO6TkgR7f_RylLb8UFNanCwYE2pDnrOJW6A1n2KdqelQOtuBrDGkr8P9YOGVVVMSdVTtSHxIzyBS1nItbggTy4-vu1FMQGdy8e4v-1cG15KchBJu7OhxtBTqQeMK7cLxN2qH3S_pB6tLZuo8_aDdS7Q2IYd2cghIKkNUY3rT1Mi6bl30BoBUmZcwtMaXeakdUWlbd906EYDegfxvd9QASR_bhbtGMNncET5WjJ2FW-jpdpi9QPMEurk0UPNQo0dJ49ljDnzvWqSfotwY7uoWa2WksuyhF5jXb9kom1a2NIFFRu4v1uWsnlGKFgr34YAqBltAQmHzhOOnnC6FaNkdKIbnpZ7swS6x-Kvl9_JenTZrXeRCK6c7YY3H1-j48xpOxcEjfR1C3_z6hg5cjBMnueeQX3l_NGio4XZ1dDfO1Uz5JUs6blR8h5Sc9sxuxwYx_JJXIYEdQZ7yBpHnnNwwDpD5Z3M2WGGJieO7Nu5P4_dreobN9skpFJwbtQIzQrX8jRgYi7b3_L1ImOoFD5oMS7s4ohl8kjOTAtyFifXJuLLz8BkyQjWw469CTD7t-V9ZiKERwrhhbYz7LiMvAGN19biSuggeLpWhlW-uM2STU85OpvCJAeITzzfiV040J_ea7H10fXdts7cmm74_S3lyCUjoNLxM92T7EEywBbmEvh33232xmcAdM7clhB4mx78oWD1pQyahIiQjj7bZtaq91yB6G0OoWntnSe8ieH76E9UetX1fzU7W4tujTtJzgpDgg__qnr--xSlu17YnErtSJTsIetlNtGfxRWUdcbYwHd6_RC-ZkMOwrkn4uJUVHQ_OzyDKsPclvbj0d8asW74Bpyan2S8sBzj3Ll7H0OqbZDXsd3emc34tFrHvWQ4IiE6vGBYC9kWAlvHQWzSMXUKpsmxaWxQy583Wwbr2HbZqAJEM863BkjPbupfx51SpKWxfL9iHvxeBOzUZlsydeo5wzq1Zxck2bS97PgO68enMShHT6a-OsQ2toA-lgJ0iDwFpJMrqLOEJJvPONVyt7kWS_LXbwHKsy3TLSqFY-RjLSkFc4z4vYEz5Cw0RsjKzUVbP5IvZB3gLLjKFPiKW0PjiPz7P7x0j0j_wdwpZ0WA6n_HiAhp6BI9je8PRZaFIwqn-1iPNRzju2pH4xhHFf_HMMx9XP97f_a_N49SYewR5K2topq3W2miD0Luge-A-P_IETF8Ihow3ruZwucqGLZhgPIITdb7DB8o1xKcQlLOjmNnERV49Eclm-DTJGeZLh3Hqw22I7PfDMS6KYHWQp2V3I75Cn93ZcqnosSUMC-mP-qduXOYligQGB8bRi2jBQra3BOVkoWUCM5zFqcUA__GYfj9bSEhnQ2c4GOqkNqQZ3Ee7848U8RcX68uj3nKUjDtb2EyERPyL4fg7hCJBoJVOekmYGfb_lOVg=",
                "id": "rs_0c72bbefaddbeae60169091b2b889c819787c9c554c0e12617",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762204459,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 584,
        "prompt_tokens": 358,
        "total_tokens": 942,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 512,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.0012575,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 8.95e-05,
          "upstream_inference_completions_cost": 0.001168
        }
      },
      "provider": "OpenAI"
    }
  }
]